Acute Major Bleeding

Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects

NCT02281201 | PHASE 3 | INTERVENTIONAL

The purpose of this study is to evaluate efficacy and safety of a Prothrombin Complex Concentrate (PCC), BE1116. BE1116 will be used for the rapid reversal of coagulopathy induced by vitamin K antagonists in Japanese subjects who require immediate correction of international normalized ratio (INR) due to a major bleed or emergency surgery.

11 Sites

11 Participants

Recruiting

20 Years to 30 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Nippon Medical School Hospital

Sendagi,Bunkyo,Japan,113-8603

Kyushu Medical Center

Chuo-ku,Fukuoka,Japan,810-8563

Nippon Medical School Chiba Hokusoh Hospital

Kamagari,Inzai,Japan,270-1694

Kurashiki Central Hospital

Miwa,Kurashiki,Japan,710-0052

Osaka National Hospital

Chuo-ku,Osaka,Japan,540-0006

Kinki University

Higashiosaka,Osaka,Japan,577-0818

National Cerebral and Cardiovascular Center

Suita,Osaka,Japan,565-0873

Tohoku University Hospital

Aoba-ku,Sendai,Japan,980-8574

National Center for Global Health and Medicine

Toyama,Shinjuku,Japan,162-0052

Osaka University Hospital

Yamadaoka,Suita,Japan,565-0871

St. Luke's International Hospital

Chuo,Tokyo,Japan,104-8560

Study Eligibility Criteria

Inclusion Criteria

* Male and female Japanese subjects greater than or equal to 20 years
* Subjects currently on vitamin K antagonist (VKA) therapy
* INR greater than or equal to 2 within 3 hours before start of BE1116 infusion
* Urgent reversal of VKA therapy for a surgical or invasive medical procedure is required within 24 hours of the start of BE1116 infusion, or presentation with an acute major bleed

Exclusion Criteria

* Subjects for whom administration of I.V. vitamin K and VKA withdrawal, alone, can adequately correct the subject's coagulopathy before the infusion of BE1116
* Subjects in whom lowering the INR to within the normal range is not a treatment goal
* Use of anticoagulants other than VKAs (or expected use within 1 day)
* Medical history for which PCCs are contraindicated
* History of thromboembolic event within 3 months of screening
* Congenital or acquired abnormality of hemostasis other than receipt of VKAs
* Administration of whole blood, plasma, plasma fractions, or platelets within 2 weeks prior to the start of BE1116 infusion
* For subjects with intracranial hemorrhage (ICH):
* Glasgow Coma Score (GCS) \< 7
* Intracerebral hematoma volume \> 30 cm3 as assessed by computed tomography (CT) scan
* For subdural hematomas: maximum thickness ≥ 10 mm, midline shift ≥ 5 mm, or acute subdural hematomas (based on neurosurgeon review)
* For subarachnoid hemorrhage: any evidence of hydrocephalus, or Hunt and Hess Scale \> 2, or concomitant subdural hematoma
* Infratentorial ICH location
* Epidural hematomas
* Intraventricular rupture of hemorrhage
* Requires surgical intervention

Additional Studies

Additional studies can be found at ClinicalTrials.gov